COMMUNIQUÉS West-GlobeNewswire
-
Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting
23/04/2026 -
Chiffre d’affaires du 1er trimestre 2026
23/04/2026 -
Q1 2026 revenue
23/04/2026 -
FSR, in Partnership with ATS, Welcomes Dr. Matt Craig to Drive Strategic Research Initiatives
23/04/2026 -
Verano Founder and Chief Executive Officer George Archos Celebrates Historic Announcement Confirming Cannabis Rescheduling to Schedule III
23/04/2026 -
Jushi Holdings Inc. Applauds President Trump and Administration for Delivering on Cannabis Rescheduling to Schedule III under the Controlled Substances Act
23/04/2026 -
Lumina Therapy Alliance Expands Silicon Valley Presence with Addition of Wise Mind Institute in Redwood City, CA
23/04/2026 -
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
23/04/2026 -
Women Are Ditching Generic Diets for Cycle-Based Wellness – This Cycle Diet App Review Explains Why
23/04/2026 -
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
23/04/2026 -
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
23/04/2026 -
Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction
23/04/2026 -
Neura Health to Expand Access to Migraine Care via LillyDirect
23/04/2026 -
Heald Partners with Thatch Marketplace to Bring First-of-its-Kind Diabetes Reversal Program to Employees
23/04/2026 -
H1 Launches Site Network Suite, the First AI-Powered Platform to Transform How Research Sites and Sponsors Engage on Clinical Trials
23/04/2026 -
Neocis and Yomi® S Named Winner of the 2026 TAG Awards for MedTech in Robotic & Procedural Innovation
23/04/2026 -
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
23/04/2026 -
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
23/04/2026 -
MAPS Celebrates 40 Years at a Defining Moment for Psychedelics
23/04/2026
Pages